

## Template letter to MDs

Dear Dr. (INSERT NAME OF OPHTHALMOLOGIST)

There is a growing number of patients with AMD that need our help.

Knowing the tremendous impact earlier diagnosis and treatment of AMD could afford our patients, we at (NAME OF PRACTICE) have acquired an AdaptDx dark adaptometer from MacuLogix. We will be performing dark adaptation testing as part of our evaluations for patients presenting with night vision difficulties, which is the earliest symptom of AMD.

The AdaptDx accurately measures the time it takes for the eyes to adapt to darkness. This allows me to identify impaired dark adaptation and further investigate to determine if a patient has AMD. Once diagnosed, I monitor AMD patients more frequently and prescribe lifestyle changes and anti-oxidants to slow disease progression. Ultimately, my goal is to catch choroidal neovascularization as soon as it happens and before vision loss occurs.

Because of our dark adaptation assessments, you will likely see advanced-stage AMD patients referred to your practice at the first sign of CNV. It is my hope that, working together, we can intervene earlier in the disease paradigm to preserve our patients' vision and quality of life.

Sincerely,

NAME OF OPTOMETRIST, OD

P.S. Go to [www.maculogix.com/adaptDx/](http://www.maculogix.com/adaptDx/) to obtain more information about the AdaptDx and the science behind its development. Some published articles about early AMD and dark adaptation are:

1. Neely D, Bray K, Huisingsh C, Clark M, et al. Prevalence of undiagnosed age-related macular degeneration in primary eye care. *JAMA Ophthalmol.* 2017;135(6):570-5.
2. Cervantes-Castañeda RA, Banin E, Hemo I, Shipgel M, Averbuhk E, Chowers I. Lack of Benefit of early awareness to age-related macular degeneration. *Eye (Lond).* 2008;22(6):777-781.
3. Curcio C, Millican C, Bailey T, Kruth H. Accumulation of cholesterol with age in human Bruch's membrane. *Invest Ophthalmol Vis Sci.* 2001;42:265-74.
4. Owsley C, Jackson GR, White M, Feist R, Edwards D. Delays in rod-mediated dark adaptation in early age-related maculopathy. *Ophthalmology.* 2001; 108:1196-202.
5. Owsley C, McGwin G, Clark ME, et al. Delayed rod-mediated dark adaptation is a functional biomarker for incident early age-related macular degeneration. *Ophthalmology.* 2016;123(2):344-351.
6. Jackson GR, Scott IU, Kim IK, Quillen, DA, Iannaccone A, Edwards JG. Diagnostic sensitivity and specificity of dark adaptometry for detection of age-related macular degeneration. *Invest Ophthalmol Vis Sci.* 2014;55(3):1427-31.